Accelerate Diagnostics Inc (AXDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Accelerate Diagnostics Inc (AXDX) has a cash flow conversion efficiency ratio of 0.090x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.07 Million) by net assets ($-56.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AXDX stock market capitalisation for the company's overall valuation and market capitalisation.
Accelerate Diagnostics Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Accelerate Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AXDX live share price for real-time trading data and today's change.
Accelerate Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Accelerate Diagnostics Inc ranked by their cash flow conversion efficiency. Review free cash flow generation of Accelerate Diagnostics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Energy Metals Corp
V:ENRG
|
0.045x |
|
WINDFALL GEOTEK
F:L7C2
|
0.592x |
|
ZyVersa Therapeutics Inc.
NASDAQ:ZVSA
|
119.987x |
|
Microlise Group PLC
LSE:SAAS
|
0.055x |
|
Ovoca Gold PLC
IR:OVXA
|
-0.136x |
|
Bluejay Diagnostics Inc
NASDAQ:BJDX
|
-0.380x |
|
Colefax Group
LSE:CFX
|
0.297x |
|
Magnum Goldcorp Inc
V:MGI
|
0.167x |
Annual Cash Flow Conversion Efficiency for Accelerate Diagnostics Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Accelerate Diagnostics Inc from 1996 to 2024. Also see AXDX asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-56.04 Million | $-24.19 Million | 0.432x | -78.64% |
| 2023-12-31 | $-19.89 Million | $-40.20 Million | 2.021x | -7.65% |
| 2022-12-31 | $-22.26 Million | $-48.73 Million | 2.189x | +62.20% |
| 2021-12-31 | $-35.07 Million | $-47.32 Million | 1.349x | +68.19% |
| 2020-12-31 | $-62.81 Million | $-50.39 Million | 0.802x | -90.86% |
| 2019-12-31 | $-7.38 Million | $-64.79 Million | 8.781x | +843.55% |
| 2018-12-31 | $57.38 Million | $-67.76 Million | -1.181x | -154.04% |
| 2017-12-31 | $119.92 Million | $-55.75 Million | -0.465x | +32.27% |
| 2016-12-31 | $77.82 Million | $-53.41 Million | -0.686x | -159.91% |
| 2015-12-31 | $133.02 Million | $-35.13 Million | -0.264x | +7.23% |
| 2014-12-31 | $65.99 Million | $-18.79 Million | -0.285x | -21.23% |
| 2013-12-31 | $41.52 Million | $-9.75 Million | -0.235x | -326.92% |
| 2012-12-31 | $14.84 Million | $-816.00K | -0.055x | -159.06% |
| 2011-12-31 | $4.82 Million | $448.48K | 0.093x | +157.91% |
| 2010-12-31 | $4.91 Million | $-789.60K | -0.161x | -177.56% |
| 2009-12-31 | $3.89 Million | $-225.66K | -0.058x | +73.47% |
| 2008-12-31 | $4.41 Million | $-963.73K | -0.218x | +30.60% |
| 2007-12-31 | $4.88 Million | $-1.54 Million | -0.315x | +19.70% |
| 2006-12-31 | $6.74 Million | $-2.64 Million | -0.392x | -136.86% |
| 2005-12-31 | $9.67 Million | $-1.60 Million | -0.165x | -59.77% |
| 2004-12-31 | $11.74 Million | $-1.22 Million | -0.104x | -972.01% |
| 2003-12-31 | $12.73 Million | $151.16K | 0.012x | +124.54% |
| 2002-12-31 | $13.74 Million | $-665.16K | -0.048x | -629.80% |
| 2001-12-31 | $9.61 Million | $-63.73K | -0.007x | -118.19% |
| 2000-12-31 | $11.26 Million | $410.61K | 0.036x | -57.03% |
| 1999-12-31 | $12.24 Million | $1.04 Million | 0.085x | -71.36% |
| 1998-12-31 | $12.36 Million | $3.66 Million | 0.296x | +202.88% |
| 1997-12-31 | $9.20 Million | $900.00K | 0.098x | -83.10% |
| 1996-12-31 | $1.90 Million | $1.10 Million | 0.579x | -- |
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-po… Read more